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Genetically modiﬁed B cells are excellent tolerogenic antigen-presenting cells (APCs) in
multiple models of autoimmunity. However, the mechanisms of action are still not com-
pletely understood. In our models, we generate antigen-speciﬁc tolerogenic B cells by
transducing naïve or primed B cells with an antigen–immunoglobulin G (peptide–IgG) con-
struct. In order to be transduced, B cells require activation with mitogens such as LPS.We
and others have found that LPS stimulation of B cells upregulates the production of IL-10, a
key cytokine for maintaining immune tolerance. In the current study, we deﬁned the role of
B-cell produced IL-10 in tolerance induction by using IL-10 deﬁcient B cells as donor APCs.
We found that peptide–IgG transduced IL-10 KO B cells have the same effects as wt B cells
in tolerance induction in an experimental autoimmune encephalomyelitis model. Moreover,
we demonstrated that the tolerogenic effect of peptide–IgG B cells was completely abro-
gated in anti-IL-10 receptor antibody treated recipients.Taken together, our results suggest
that tolerance induced by peptide–IgG B-cell gene therapy requires IL-10 from the host but
not donor B cells. These data shed important insights into the mechanisms of tolerance
induction mediated by B-cell gene therapy.
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INTRODUCTION
Immune tolerance to self-antigens must be maintained or autoim-
munity occurs. Based on the excellent tolerogenicity of IgG
(Aldo-Benson and Borel, 1976; Borel et al., 1976) and the capac-
ity of B cells to be tolerogenic antigen-presenting cells (APCs;
Eynon and Parker, 1992; Fuchs and Matzinger, 1992; Gilbert
and Weigle, 1994), our laboratory has developed a B-cell based
gene therapy approach for actively inducing tolerance in ani-
mal models of autoimmune diseases and hemophilia (Skupsky
et al., 2007). For example, when retrovirally transduced with a
fusion construct encoding IgG heavy chain and factor VIII (fVIII)
immunodominant domain C2 or A2, B cells are tolerogenic in
both naïve and fVIII-primed hemophilic mice (E16, fVIII−/−)
as measured by speciﬁc cellular response and inhibitory anti-
body titers (Lei and Scott, 2005). In experimental autoimmune
encephalomyelitis (EAE), myelin oligodendrocyte glycoprotein
(MOG)–IgG, or myelin basic protein (MBP)–IgG transduced B
cells can protect mice from EAE (Xu and Scott, 2004; Zhang et al.,
2010). In other models of autoimmune diseases including experi-
mental autoimmune uveitis, type I diabetes, and arthritis, animals
that received peptide–IgG transduced B cells exhibited reduced
speciﬁc humoral and cellular responses, delayed disease onset, and
amelioration of ongoing disease (Agarwal et al., 2000; Melo et al.,
2002; Soukhareva et al., 2006; Satpute et al., 2007). Achievement of
antigen-speciﬁc tolerance in these models indicates the promise of
this method as therapy for patients with autoimmune diseases or
hemophiliacs with fVIII inhibitor formation. Similar results were
reported by several other groups where B cells were also utilized
for tolerance induction in EAE (Chen et al., 2001, 2004) and in a
mouse model of asthma (Ahangarani et al., 2009).
The underlying mechanisms for tolerance induction by B-cell
delivered gene therapy remains incompletely understood. IL-10
is a key regulator of immune-suppression and for maintenance
of peripheral tolerance (Kuhn et al., 1993). Originally, IL-10 was
deﬁned as a Th2 cytokine that inhibits Th1 T-cell responses
(Fiorentino et al., 1989). Later studies suggest that IL-10 can be
produced by multiple types of T cells including CD4+CD25+ reg-
ulatory T cells (Tregs), as well as APCs. In the resting state, B
cells produce only low levels of IL-10. However, activated B cells
dramatically upregulate the production of IL-10 (Fillatreau et al.,
2002; Barr et al., 2007; Lampropoulou et al., 2008). Whether IL-
10 is involved in the mechanisms of tolerance induction by B-cell
based gene therapy remains controversial. Ahangarani et al. (2009)
demonstrated that genetically modiﬁed B cells can induce toler-
ance in an allergy model in an IL-10 dependent manner. On the
other hand, Frommer et al. (2008) found that production of IL-10
by MOG presenting B cells plays no role in tolerance induction in
an EAE model. To optimize our B-cell based gene therapy protocol
for future clinical study, we screened multiple mitogens for B-cell
activation and, interestingly, found that the manner of B-cell acti-
vation was critical for tolerance induction. Thus, LPS-activated
B cells are tolerogenic, but unmethylated DNA CpG stimulated
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B cells are not (Lei et al., 2005). Further investigation indicated
that LPS-treated B cells produce signiﬁcantly higher amounts
of IL-10 than CpG-treated B cells (Skupsky et al., 2007). These
ﬁndings raise an interesting question regarding the mechanisms
of tolerance induction: Do B cells really need IL-10 to induce
tolerance?
In the current study, the role of IL-10 was tested by using IL-10
KO mice as B-cell donors or by treating recipient animals with
an anti-IL-10 receptor (IL-10R) antibody. We found that IL-10
produced by host but not by donor B cells is critical for tolerance
induction. Since we previously showed that CD4+CD25+ Tregs
were required for the induction and maintenance of tolerance (Lei
and Scott, 2005; Soukhareva et al., 2006), we propose that these
cells may be the source of endogenous IL-10 in the host.
MATERIALS AND METHODS
MICE
C57BL/6,Balb/c,membraneovalbumin expressing (mOVA) trans-
genic, and H-2b IL-10 KO mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). H-2d IL-10 KO mice were
a kind gift from Dr. Wendy Davidson (University of Maryland
School of Medicine, Baltimore, MD, USA). All recipient animals
were used at 5–8weeks of age and housed in pathogen-free micro-
isolator cages in the animal facility at the University of Maryland,
Baltimore. All animal experiments were approved by IACUC of
University of Maryland School of Medicine.
ANTIBODIES
Anti-IL-10R (1B1.3a, rat IgG1) and control mAb (GL113, anti-
E.coli β-galactosidase, rat IgG1) hybridomas were originally pro-
vided by Dr. Kevin Moore (DNAX, Palo Alto, CA, USA). The
anti-IL-10R and control mAbs used in vivo were puriﬁed from
ascites produced in nude mice by ammonium sulfate precipitation
and ion exchange chromatography (Harlan Bioproducts).
VIRUS-PRODUCING CELL LINES
The cDNAof the peptide–IgG1 heavy chainwas subcloned into the
murineMoloney leukemia retroviral vector (MBAE), as previously
described (Zambidis et al., 1997a,b). Brieﬂy, a DNA fragment of
pOVA323–339 or full-length OVA was inserted into the BSSK-IgG
vector and then the IgG fusion construct was subsequently sub-
cloned into the MBAE retroviral vector. Virus-producer cell line
was prepared by stable transfection of GP + E86 packaging cells
with the engineered construct. Viral producing packaging cells
weremaintained inDMEMmedium supplementedwith 10%FBS,
2mM L-glutamine, and 2-mercaptoethanol.
B-CELL PURIFICATION AND RETROVIRAL TRANSDUCTION
Splenic B cells from naïve mice were puriﬁed to approximately
95% homogeneity with anti-T-cell antibody cocktail (anti-Thy1,
anti-CD4, and anti-CD8) followed by complement (Low-Tox-
M, Cedarlane Laboratories, Accurate Chemical and Scientiﬁc
Corporation, Westbury, NY, USA). Puriﬁed B cells were pre-
stimulated with 1 μg/ml LPS (E. coli 055:B5, Sigma, St. Louis,
MO, USA) overnight and then transduced in vitro via co-culture
with 1500 rad irradiated virus-producing packaging cells for 24 h
in the presence of 6μg/ml polybrene.
TOLERANCE INDUCTION TO OVA AND T-CELL PROLIFERATION ASSAY
1× 107 pOVA323–339-IgG or OVA–IgG transduced wt or IL-10
KO B cells were transferred into naïve mice intraperitoneally.
One week later, recipient mice were immunized with 25 μg OVA
protein emulsiﬁed in CFA in one hind footpad and the base of
tail. Two weeks after immunization, mice were bled and then
sacriﬁced. Draining inguinal and popliteal LNs were removed
for T-cell proliferation assay. Single cell solution was prepared
at 5× 106 cells/ml. One hundred microliter cells were seeded
onto 96-well plate in the presence of indicated concentrations
of pOVA peptide. 48 h later, cell culture were pulsed with 1 μCi
[3H] thymidine (Amersham Life Sciences, Arlington Heights, IL,
USA) and incubated for another 16–20 h. Cells were then har-
vested on glass ﬁber ﬁlters and [3H] thymidine incorporation
was counted by using Scintillation Counter. Data were presented
as mean cpm (count per minute by subtraction of the back-
ground)± SE. Anti-OVA–IgG titers were determined by endpoint
ELISA methods.
IL-10R BLOCKING IN VIVO
Anti-IL-10R (1B1.3a, rat IgG1) mAb was used to block IL-10
function in vivo and anti-E.coli β-galactosidase was used as iso-
type control. Mice were received B-cell gene therapy (retrovirally
transduced wt B cells or mOVA transgenic B cells in different
experiments) on day 0 and challenged on day 7. These recipient
mice were injected four times on day −3, 0, 7, and 14, respectively.
Each time 1mg/mouse of anti-IL-10R or controlmAbwas injected
intraperitoneally.
B-CELL GENE THERAPY FOR TOLERANCE INDUCTION IN MURINE EAE
One week before the active induction of EAE, C57BL/6 (B6)
were adoptively transferred with 1× 107 retrovirally transduced
syngeneic tolerogenic B cells expressing MOG35–55–Ig (MOG–
Ig), intraperitoneally. For EAE induction, 6-week-old female B6
mice were subcutaneously immunized on the ﬂanks with 200 μg
of MOG35–55 peptide emulsiﬁed in CFA containing 4mg/ml of
Mycobacterium tuberculosis H37Ra (DIFCO, Detroit, MI). On the
day of immunization and 48 h later, the mice also received 200 ng
of Pertussis toxin (Sigma-Aldrich) in 0.2ml PBS intraperitoneally.
Clinical signs of EAE were assessed daily with a 0–5 scoring system
(Stromnes andGoverman,2006): 0,normal; 0.5, partially limp tail;
1, paralyzed tail; 2, loss in coordinated movement; 2.5, one hind
limb paralyzed; 3, hind limbs paralyzed; 3.5, hind limbs paralyzed
and forelimbs weakness; 4, forelimbs paralyzed; 5, moribund.
STATISTICS
Paired or unequal variances one-tailed Student’s t -test statistics
were applied with differences considered signiﬁcant at *p < 0.05.
RESULTS
IL-10 PRODUCED BY DONOR B CELLS IS NOT REQUIRED FOR
TOLERANCE INDUCTION
Our laboratory has successfully applied the B-cell based peptide–
IgG gene therapy protocol in multiple animal models for autoim-
munity such as type 1 diabetes, EAE, experimental autoimmune
uveitis, and also in a mouse model for hemophilia A. In this gene
therapy protocol, B cells have to be activated before retroviral
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transduction as only dividing cells can be effectively transduced
with the peptide–IgG construct.We routinely use LPS to stimulate
B cells. Other B-cell mitogens such as anti-IgM and anti-CD40
have similar effects as LPS on B cells in term of tolerance induc-
tion. Surprisingly, although it could activate B cells effectively,
unmethylated CpG DNA stimulation results in B cells losing
their tolerogenic phenotype (Lei et al., 2005). We systematically
compared the phenotypic changes of B cells upon LPS and CpG
stimulation. Compared to the resting B cells, although both LPS
and CpG B-cell blasts have upregulated expression of IL-10 at pro-
tein and messenger RNA levels, LPS B cells produce much more
IL-10 than CpG B cells (Skupsky et al., 2007). These ﬁndings,
together with the contradict reports from the literature, led us to
ask whether IL-10 is critical for tolerance induction through our
B-cell delivered gene therapy protocol. Therefore, in the current
study, we ﬁrst studied the role of B-cell derived IL-10 in our gene
therapy system by using H-2d IL-10 KO mice as B-cell donors. We
transduced LPS-activated B cells with a retroviral construct encod-
ing an immunodominant epitope 323–339 fragment of ovalbumin
(OVA) and IgG1 heavy chain (pOVA323–339–IgG) or a mock con-
trol (phospholipid protein, PLP). As expected, mice that received
pOVA323–339–IgG transduced wt B cells exhibited reduced anti-
OVA antibody. Surprisingly, pOVA323–339–IgG transduced IL-10
KO B cells also induced a signiﬁcant reduction of antibody to
OVA (Figure 1). This suggests that IL-10 KO B cells have nor-
mal antigen-presenting function and more importantly, that IL-10
produced by donor B cells is not required for tolerance induction.
In addition, both pOVA323–339–IgG transduced wt or IL-10 KO B
cells signiﬁcantly reduced the T-cell response to pOVA323-339 in
recipients. We conﬁrmed these results by using H-2b IL-10 KO B
cells as donors to induce tolerance to OVA protein in C57BL/6
mice (data not shown).
To validate that IL-10 produced by tolerogenic B cells is not
required for tolerance induction, we used IL-10 KO B cells as
tolerogenic APCs to induce tolerance in the EAE model. We have
previously showed that MOG–IgG transduced B cells were highly
tolerogenic and adoptive transfer of MOG–IgG B cells protected
recipients from EAE induction (Zhang et al., 2010). In the current
study, we ﬁrst transduced IL-10 KO C57BL/6 B cells with MOG–
IgG or a mock control (OVA–IgG). Transduced B cells (1× 107)
were injected intraperitoneally into naïve C57BL/6 mice 1week
before active induction of EAE with MOG35–55. After EAE induc-
tion, we monitored the disease development daily. We found that
MOG–IgG transducedwtB cells protectedmice fromEAE in terms
of mean disease score and disease incidence during the early phase
of the disease development (Figures 2A,B). However, we observed
an overlap of the average clinical scores in the end of this exper-
iment. Based on our previous ﬁndings (Zhang et al., 2010), we
believe this is due to the relatively short observation period and
does not indicate that the disease protection by wt B cells was tran-
sient. Interestingly, MOG–IgG transduced IL-10 KO B cells also
protected mice from EAE, suggesting that IL-10 deﬁciency does
not affect tolerance inducing property of B cells (Figures 2A,B).
Furthermore, in a hemophilia mouse model, we found that fVIII
domain C2–IgG transduced IL-10 KO B cells are tolerogenic to C2
peptide in vivo (data not shown). Taken together, we conﬁrmed
that tolerance induction by our B-cell gene therapy protocol does
FIGURE 1 | Donor B cells from IL-10 KO mice are tolerogenic. (A)
LPS-activated wt or IL-10 KO B cells were transduced with pOVA323–339–IgG
or a mock control vector (PLP–IgG) and 1× 107 B cells per mouse were
injected i.p. into naïve Balb/c recipients. Seven days later, mice were
immunized with 25μg OVA protein emulsiﬁed in CFA via a hind footpad and
the base of tail. Two weeks after immunization, sera were collected and
assayed for total anti-OVA–IgG by the endpoint ELISA method (n = 4). (B)
Animals were treated as described in Figure 1A. Mice were sacriﬁced
2weeks after immunization and draining lymph nodes were removed for
CD4+ T-cell proliferation assay. Five× 105 cells from draining LNs were
seeded per well in 96-well plates in the presence of indicated
concentrations of p323–339. After 48 h, cultures were pulsed with
1μCi/well of [3H] thymidine (Amersham Life Sciences, Arlington Heights,
IL, USA) and incubated for another 16–20 h. Cells were then harvested on
glass ﬁber ﬁlters andT-cell proliferation to p323–339 was determined by
[3H] thymidine incorporation. Values represent mean cpm (count per
minute by subtraction of the background)±SE for four animals. Data are
representative of two independent experiments.
not depend on the IL-10 produced by donor B cells in multiple
animal models from different genetic background.
IL-10 PRODUCED BY THE HOST IS REQUIRED FOR TOLERANCE INDUCED
BY PEPTIDE–IGG EXPRESSING B CELLS
In multiple models of infection and autoimmune diseases, mice
that are genetically deﬁcient in IL-10 exhibit dramatically exacer-
bated diseases (Kuhn et al., 1993; Bettelli et al., 1998; Yin et al.,
2002). Since IL-10 plays such a critical role in immune regula-
tion and maintenance of tolerance, we next sought to ask whether
IL-10 produced by the host is required for tolerance induction in
our model. To this end, we utilized in vivo anti-IL-10R antibody
treatment to block IL-10 function in normal mice, rather than
using IL-10 KO mice which have an autoimmune syndrome. Fol-
lowing the standard tolerance induction protocol, LPS-activated,
OVA–IgG transduced B cells were transferred into naïve mice on
day 0. On day −3, 0, 7, and 14, recipients were injected four times
with anti-IL-10R or control rat IgG1 mAb. These recipients were
immunized with OVA protein in CFA on day 7 and the effect
of anti-IL-10R blocking on tolerance induction was evaluated on
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FIGURE 2 | IL-10 deficient B cells are tolerogenic in an EAE model.
Female C57BL/6 recipients (n = 5) were adoptively transferred with 1× 107
retrovirally transduced B cells. One week later, the mice were actively
immunized for EAE induction using MOG35–55 (200μg)/CFA. The mice were
also received 200 ng Pertussis toxin in 0.2ml PBS via i.p. injection at the same
day and 2 days after immunization. The clinical score was monitored daily
using a 0–5 scoring system. Mean disease score (A) and the disease
incidence (B) were shown. As the mice that received MOG–Ig transduced B
cells from wt C57BL/6 donors (left panels), the mice that received MOG–Ig
transduced IL-10 KO B cells (right panels) also had ameliorated disease
symptoms and decreased disease incidence, as compared with the
control.
day 21 by testing in vitro T-cell response and antibody titer. As
expected, control mAb treatment has no effect on the hypore-
sponsiveness induced by OVA–IgG B cells (Figures 3A,B). Mice
that received OVA–IgG transduced B cells and control mAb treat-
ment exhibited reducedT-cell and antibody responses againstOVA
protein.However, in anti-IL-10R treatedmice, tolerance induction
was completely abrogated, suggesting that IL-10 produced by the
host is required for tolerance induction.
To conﬁrm these results, we used another model in which
mOVA transgenic B cells were used as APCs. We have found
that both resting and LPS-activated mOVA B cells are tolerogenic
in vivo (Su et al., in preparation). In this study, we ﬁrst transferred
LPS-activatedmOVAB cells towtmice and challenged these recip-
ients 1 week later. The recipients were treated with anti-IL-10R or
control mAb four times on day −3, 0, 7, and 14. We assayed T-
cell and antibody responses on day 21. Again, the tolerogenicity of
mOVABcells was abrogated by in vivo IL-10Rblockade (Figure 4).
Together, our data in both systems suggest that host IL-10 produc-
tion is required for genetic engineered B-cell mediated tolerance
induction.
DISCUSSION
Adoptive transfer of target-antigen expressing B cells has been
demonstrated to be able to induce antigen-speciﬁc tolerance in
various animal models such as EAE, allergy, and hemophilia. In
this study, we deﬁned the role of IL-10 in an established B-cell
based gene therapy system for tolerance induction. We demon-
strated that antigen-speciﬁc tolerance does not need IL-10 gener-
ated by peptide–IgG transduced tolerogenic B cells. Rather, IL-10
produced by the host is required for tolerance induction.
B cells play an important role in controlling autoimmunity.
For example, B-cell deﬁcient mice lose the ability of recovery from
clinical disease symptoms after EAE induction (Wolf et al., 1996).
It has been found that IL-10 produced by B cells is critical at
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FIGURE 3 | IL-10 produced by the host is required for tolerance
induction by peptide–IgG transduced B cells. LPS-activated wt B cells
were transduced with OVA–IgG or a mock control vector (PLP) and 1× 107
B cells per mouse were injected i.p. into naïve C57BL/6 recipients on day 0.
Seven days later, mice were immunized with 25μg OVA protein emulsiﬁed
in CFA via a hind footpad and the base of tail. Two weeks after
immunization, mice were sacriﬁced and assayed for CD4+ T-cell and
antibody responses. On day −3, 0, 7, and 14, mice were injected i.p. four
times with 1mg/mouse of anti-IL-10R (1B1.3a, rat IgG1) or control mAb
(GL113, anti-E.coli β-galactosidase, rat IgG1). The antibody (A) andT-cell
responses (B) were assayed and presented as described in Figure 1
legend. Values represent mean±SE of antibody titers or mean cpm±SE.
(n = 4). Data are representative of two independent experiments.
FIGURE 4 | IL-10 produced by the host is required for tolerance
induction by transgenic tolerogenic B cells. One× 107 B LPS-activated
mOVA or wt B cells were injected into wt C57BL/6 mice. Tolerance
induction protocol, anti-IL-10R treatment, and assay method are same as
described in Figures 1 and 3 (n = 4). Data are representative of two
independent experiments.
the remission stage of EAE as B-cell restricted IL-10 deﬁciency
results in mice that fail to recover from EAE (Fillatreau et al.,
2002). Recently, Carter et al. (2011) demonstrated that in an
arthritis model, IL-10-producing B-cell deﬁcient mice exhibited
an exacerbated disease symptom. In these IL-10-producing B-cell
deﬁcient mice, a decrease of FoxP3+Tregs and an increase of Th1
and Th17 cells were found. These ﬁndings indicate that IL-10-
producing B cells might have a regulatory cell phenotype and the
IL-10 produced by B cells plays an essential role in regulation of
autoimmunity.
Several years ago,wedemonstrated that bonemarrowcells from
IL-10 KO mice could be transduced to be tolerogenic for a cog-
nate antigen (El-Amine et al., 2000). In addition, Frommer et al.
(2008) showed that IL-10 produced by B cells is not required for
tolerance induction in an EAE model. In that study, EAE resistant
mice that express MOG on B cells (BMOG) were crossed with IL-
10 deﬁcient mice to generate IL-10 KO MOG expressing B cells.
They found that IL-10 KO transgenic mice were tolerant and were
resistant to MOG-induced EAE. Recently, Calderon-Gomez et al.
(2011) validated this result using lentiviral transduction of B cells.
In sum, these results suggested that transduced or transgenic B
cells tolerize T cells in an IL-10 independent manner.
In contrast, Ahangarani et al. (2009) recently found that IL-10
produced by target-antigen expressing B cells is critical for toler-
ance in an allergic model. This is of our particular interest because
the B-cell gene therapy protocol used in this study is similar as
ours. In the allergy model, B cells that express a fusion protein of
an endosomal targeting sequence (gp75) and a major T-cell epi-
tope of a common allergen,Der p2, induced tolerance to Der p2 in
mice upon peptide immunization. Although detailed mechanisms
were not fully elucidated, it was found that genetically modiﬁed B
cells induced type 1 regulatory T cells (Tr1) in an IL-10 dependent
manner (Ahangarani et al.,2009). In a follow-up study,Ahangarani
et al. (2011) demonstrated that retroviral particles could bind and
activate Toll-like receptor 2 on transduced B cells and in turn, acti-
vation of Toll-like receptor 2 results in upregulated production of
IL-10 through STAT3 signaling pathway.
In our system, themechanisms of tolerance induction appear to
be different. We previously demonstrated that transduced B cells
tolerize recipient animals in a MHC class II dependent manner
(Litzinger et al., 2005; Su et al., 2008) and that tolerance induced
by peptide–IgG expressing B cells depends on activation of nat-
ural CD4+CD25+ Tregs and/or generation of inducible Tregs (Lei
and Scott, 2005; Soukhareva et al., 2006; Skupsky et al., 2010).
Depletion of CD4+CD25+ Tregs completely abrogates the toler-
ance induction by peptide–IgG transduced B cells (Lei and Scott,
2005; Soukhareva et al., 2006).We also demonstrated that peptide–
IgG transduced B cells could induce an increase of FoxP3+ Tregs in
recipient animals and a reduction of the CD4+ effector T-cell pop-
ulation (Skupsky et al., 2010). Moreover, we recently observed by
two-photon microscopy that tolerogenic B cells tightly conjugate
with target CD4+ T cells and this B:T conjugation is CTLA-4/B7
dependent (Su et al., in preparation). Taken together, these obser-
vations suggest that in our system, B cells induce tolerance by
induction of antigen-speciﬁc CD4+CD25+ Tregs through direct
B:T contact. In addition, the IgG heavy chain might also play a
role in induction/activation of CD4+CD25+ Tregs. We previously
showed that the IgG heavy chain enhances the degree of tolerance
and promotes the hyporesponsive state induced by B-cell gene
therapy (Kang et al., 1999; Lei et al., 2005).
Recently, several highly promiscuous major histocompatibil-
ity complex class II regulatory T-cell epitopes (Tregitopes) in the
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conserved regions of IgG were identiﬁed (De Groot et al., 2008).
Indeed,we suggest that these IgG epitopesmay enhance the tolero-
genic properties of the fusion constructs utilized in our B-cell gene
therapy system. We found that in vivo administration of Tregit-
opes can stimulate natural Tregs in DO11.10 transgenic mice and
delivery of these Tregitopes with OVA protein by B cells also pro-
tect mice from antigen challenge (Su et al., in preparation). Based
on these observations, we propose that the exogenous IL-10 pro-
duced by tolerogenic B cells is not required for inducing/activating
CD4+CD25+ Tregs in the early stage and maintaining tolerance.
Thus, we believe that the distinct roles of IL-10 played in these two
studies (our work andAhangarani et al., 2009) are likely due to the
different model systems used, i.e., whether the fusion construct
expresses IgG, whether natural Tregs or Tr1 cells are induced, or
whether an endosomal targeting sequence is utilized.
Nevertheless, our data suggest that the endogenous IL-10 pro-
duced by the host is essential for tolerance induction. We have
previously shown that both Th1 and Th2 responses in host mice
are reduced by peptide–IgGB-cell gene therapy (Kang et al., 1999).
Therefore, it is unlikely that the in vivo IL-10Rblockade has skewed
the Th1 and Th2 populations directly. Instead, we suggest that
the IL-10R blockade affects the activation or function of natural
CD4+CD25+ Tregs or inducible Tregs, which we have shown to
be integral for the efﬁcacy of B-cell gene therapy. The endoge-
nous IL-10 could be produced by different subsets of lymphocytes
including regulatory T cells. One of the suppressivemechanisms of
Tregs is through producing IL-10. IL-10 produced by APCs is also
important for induction of Tregs. For example, IL-10 produced
by macrophages in the lamina propria is critical for conversion
of Tregs from convention T cells in mucosal immunity (Denning
et al., 2007;Murai et al., 2009;Hadis et al., 2011). In addition, it has
been demonstrated recently that transitional two marginal zone B
cells, which are IL-10-producing and have regulatory phenotypes,
play an important role in inducing FoxP3 Tregs and suppress-
ing Th1 and Th17 cells (Carter et al., 2011). Therefore, although
in our system exogenous IL-10 from donor B cells is dispensable
for inducing tolerance, blocking endogenous IL-10 from the host
interrupt tolerance induced by peptide–IgG B cells possibly due
to at least two mechanisms: inﬂuence the induction or conver-
sion of Tregs from conventional T cells or interfere the function
of Tregs.
In summary, several groups have utilized B cells to deliver tol-
erance via gene therapy. Here we demonstrate that host IL-10 is
critical for the tolerogenicity of B-cell based peptide–IgG gene
therapy in vivo and that IL-10 produced by B cells themselves is
not required for tolerance induction.
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